These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22926944)

  • 1. Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.
    Zhang GC; Liao N; Guo ZB; Qian XK; Ren CY; Yao M; Li XR; Wang K; Zu J
    Clin Transl Oncol; 2013 Jan; 15(1):79-84. PubMed ID: 22926944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Chen M; Li S; Huang M; Guo J; Huang X; Guo W; Chen L; Lin Y; Jacobs L; Wang C; Fu F
    Breast Cancer Res Treat; 2022 Nov; 196(2):267-277. PubMed ID: 36100784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    El Hage Chehade H; Headon H; Kasem A; Mokbel K
    Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
    Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
    Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR
    Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
    Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
    Breast J; 2022; 2022():1507881. PubMed ID: 36051467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    Fu JF; Chen HL; Yang J; Yi CH; Zheng S
    PLoS One; 2014; 9(9):e105316. PubMed ID: 25210779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Park S; Koo JS; Kim GM; Sohn J; Kim SI; Cho YU; Park BW; Park VY; Yoon JH; Moon HJ; Kim MJ; Kim EK
    Cancer Res Treat; 2018 Jul; 50(3):801-812. PubMed ID: 28814071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.
    Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T
    Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.
    Takahashi M; Jinno H; Hayashida T; Sakata M; Asakura K; Kitagawa Y
    World J Surg; 2012 Dec; 36(12):2847-52. PubMed ID: 22806206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
    Chintamani ; Tandon M; Mishra A; Agarwal U; Saxena S
    World J Surg Oncol; 2011 Feb; 9():19. PubMed ID: 21396137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
    Wu D; Liu SY; Amina M; Fan ZM
    Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer.
    Shimazu K; Noguchi S
    Surg Today; 2011 Mar; 41(3):311-6. PubMed ID: 21365408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.